SG
VTGN icon

StoneX Group’s VistaGen Therapeutics VTGN Stock Holding History

StoneX Group’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.62K Sell
10,840
-4,358
-29% -$2.63K ﹤0.01% 1395
2026
Q1 		$8.69K Buy
15,198
+1,849
+14% +$1.12K ﹤0.01% 856
2025
Q4 		$8.84K Buy
+13,349
New +$48.2K ﹤0.01% 1009

Other funds holding VTGN

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CWS
Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return
RS
R Squared Central, Hong Kong $190M AUM 25.89% 1-Year Est. Return

StoneX Group's VTGN Position: Q2 2026 in Review

StoneX Group reduced its VistaGen Therapeutics (VTGN) stake by 29% in Q2 2026, selling an estimated $2.63K and leaving 10,840 shares worth $6.62K. The position accounts for ﹤0.01% of the portfolio, ranked #1395.

StoneX Group first reported a position in VTGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.84K in Q4 2025. 25 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • StoneX Group held 10,840 shares of VistaGen Therapeutics worth $6.62K as of Q2 2026.
  • StoneX Group sold 4,358 VistaGen Therapeutics shares in Q2 2026, an estimated $2.63K.
  • VistaGen Therapeutics made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1395 holding.
  • StoneX Group first reported a position in VistaGen Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • StoneX Group's VistaGen Therapeutics position peaked at $8.84K in Q4 2025.
  • 25 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.